Sionna Therapeutics, Inc. SION 深 沪
等待开盘 12-22 09:30:00 美东时间
42.37
-1.840
-4.16%
华盛通- 最 高45.00
- 今 开43.70
- 成交量 195.47万股
- 最 低 42.24
- 昨 收 44.21
- 总市值 18.70亿
- 52周最高 45.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.255
- 委 比 94.92%
- 总股本 4413.98万
- 历史最高 45.00
- 量 比 7.07
- 振 幅 6.24%
- 历史最低 7.255
- 每 手 1
- 风险率 10.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
RBC Capital Downgrades Sionna Therapeutics to Underperform, Maintains Price Target to $24
RBC Capital analyst Brian Abrahams downgrades Sionna Therapeutics (NASDAQ:SION) from Sector Perform to Underperform and maintains the price target from $24 to $24.
12-01 22:27
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
BTIG Initiates Coverage On Sionna Therapeutics with Buy Rating, Announces Price Target of $50
BTIG analyst Kambiz Yazdi initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and announces Price Target of $50.
11-19 18:14
Sionna Therapeutics Q3 EPS $(0.46) Beats $(0.49) Estimate
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.49) by 6.69 percent. This is a 91.89 percent increase over losses of $(5.67) per share
11-05 20:11
Metsera Receives Unsolicited Proposal from Novo Nordisk
Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Met...
10-30 19:07
Lilly to Acquire Adverum Biotechnologies
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition ali...
10-24 20:30
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
Sionna Therapeutics announced data at the 2025 North American Cystic Fibrosis Conference showing that its first-in-class NBD1 stabilizers, SION-719 and SION-451, were generally well-tolerated in Phase 1 trials and exceeded pharmacokinetic targets. New preclinical data revealed that these stabilizers restored the half-life of the F508del-CFTR protein to wild-type levels, potentially offering a significant advancement in CF treatment. The company i...
10-24 17:15
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH J...
10-22 19:00
美股牛股 | 散户追捧+业务规模扩大！BYND大涨146.3%；生物技术股RANI涨26.7%
散户追捧+业务规模扩大！BYND大涨146.3%，近三交易日涨约6倍；生物技术股RANI涨26.7%，与中外制药达成重大合作协议>>
10-22 14:01
